Search results
3 dni temu · Table 1 Patient characteristics for all advanced non-small cell lung cancer patients treated with 1 L pembrolizumab mono- or combination therapy in Norway (real-world) or clinical trials (Keynote ...
4 wrz 2024 · A new benchmark for targeted therapies in lung cancer treatment. AEs, adverse events; HR, hazard ratio; NR, not reached; PFS, progression-free survival. Open in viewer.
1 lip 2022 · We curated and analyzed a comprehensive list of therapeutic entities (TEs) in preclinical development and clinical trials for lung cancer. Results On the basis of our analysis of 707 TEs, we found a consistent forward trajectory in the development pipeline for both NSCLC and SCLC.
6 kwi 2024 · Monica Casiraghi, Clarissa Uslenghi, Sebastiano Maiorca & Lorenzo Spaggiari. 976 Accesses. 3 Citations. 1 Altmetric. Explore all metrics. Abstract. Lung cancer, a multifaceted disease, demands tailored therapeutic approaches due to its diverse subtypes and stages.
8 sie 2024 · Two studies presented during this year’s plenary session at the American Society of Clinical Oncology (ASCO) meeting highlight the ongoing advances in lung cancer treatments for earlier stages of the disease in specific populations of patients.
19 sie 2024 · This review examines the latest discoveries in the genetics of lung cancer, discusses key biomarkers, and analyzes current clinical therapies based on this genetic information. It will conclude with a discussion of future prospects and potential research directions.
5 sie 2024 · We found that the survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC (non-small cell lung cancer) but not in SCLC (small cell lung cancer). SCLC remains a disease with poor prognosis for which novel therapies are needed.
